The European Medicines Agency confirmed it will turn an EU-level trial advice pilot into a permanent option for sponsors. The change allows drug developers in the EU to continue seeking structured regulatory input under the program framework rather than relying on a time-limited pilot. For biotech sponsors, earlier regulator touchpoints can reduce uncertainty in trial design and eligibility pathways—especially for novel mechanisms and small populations. The move also signals that EMA sees the pilot’s value in operationalizing guidance, aligning with a broader push toward more consistent advice as trials scale across member states.